tetano
Editor, Senior Moderator
J Virol
. 2024 Jul 30:e0078124.
doi: 10.1128/jvi.00781-24. Online ahead of print. rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose
Kristin B Wiggins[SUP] #[/SUP][SUP] 1 2 [/SUP], Stephen M Winston[SUP] #[/SUP][SUP] 1 3 [/SUP], Isaiah L Reeves[SUP] 1 3 [/SUP], Jessica Gaevert[SUP] 1 2 [/SUP], Yunyu Spence[SUP] 3 [/SUP], Mark A Brimble[SUP] 2 [/SUP], Brandi Livingston[SUP] 2 [/SUP], Christopher L Morton[SUP] 3 [/SUP], Paul G Thomas[SUP] 2 [/SUP], Andrea J Sant[SUP] 4 [/SUP], Ted M Ross[SUP] 5 6 [/SUP], Andrew M Davidoff[SUP] 1 3 [/SUP], Stacey Schultz-Cherry[SUP] 1 2 [/SUP]
Affiliations
Influenza remains a worldwide public health threat. Although seasonal influenza vaccines are currently the best means of preventing severe disease, the standard-of-care vaccines require frequent updating due to antigenic drift and can have low efficacy, particularly in vulnerable populations. Here, we demonstrate that a single administration of a recombinant adenovirus-associated virus (rAAV) vector expressing a computationally optimized broadly reactive antigen (COBRA)-derived influenza H1 hemagglutinin (HA) induces strongly neutralizing and broadly protective antibodies in naïve mice and ferrets with pre-existing influenza immunity. Following a lethal viral challenge, the rAAV-COBRA vaccine allowed for significantly reduced viral loads in the upper and lower respiratory tracts and complete protection from morbidity and mortality that lasted for at least 5 months post-vaccination. We observed no signs of antibody waning during this study. CpG motif enrichment of the antigen can act as an internal adjuvant to further enhance the immune responses to allow for lower vaccine dosages with the induction of unique interferon-producing CD4+ and CD8+ T cells specific to HA head and stem peptide sequences. Our studies highlight the utility of rAAV as an effective platform to improve seasonal influenza vaccines.
Importance: Developing an improved seasonal influenza vaccine remains an ambitious goal of researchers and clinicians alike. With influenza routinely causing severe epidemics with the potential to rise to pandemic levels, it is critical to create an effective, broadly protective, and durable vaccine to improve public health worldwide. As a potential solution, we created a rAAV viral vector expressing a COBRA-optimized influenza hemagglutinin antigen with modestly enriched CpG motifs to evoke a robust and long-lasting immune response after a single intramuscular dose without needing boosts or adjuvants. Importantly, the rAAV vaccine boosted antibody breadth to future strains in ferrets with pre-existing influenza immunity. Together, our data support further investigation into the utility of viral vectors as a potential avenue to improve our seasonal influenza vaccines.
Keywords: adeno-associated virus; influenza vaccines.
. 2024 Jul 30:e0078124.
doi: 10.1128/jvi.00781-24. Online ahead of print. rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose
Kristin B Wiggins[SUP] #[/SUP][SUP] 1 2 [/SUP], Stephen M Winston[SUP] #[/SUP][SUP] 1 3 [/SUP], Isaiah L Reeves[SUP] 1 3 [/SUP], Jessica Gaevert[SUP] 1 2 [/SUP], Yunyu Spence[SUP] 3 [/SUP], Mark A Brimble[SUP] 2 [/SUP], Brandi Livingston[SUP] 2 [/SUP], Christopher L Morton[SUP] 3 [/SUP], Paul G Thomas[SUP] 2 [/SUP], Andrea J Sant[SUP] 4 [/SUP], Ted M Ross[SUP] 5 6 [/SUP], Andrew M Davidoff[SUP] 1 3 [/SUP], Stacey Schultz-Cherry[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39078191
- DOI: 10.1128/jvi.00781-24
Influenza remains a worldwide public health threat. Although seasonal influenza vaccines are currently the best means of preventing severe disease, the standard-of-care vaccines require frequent updating due to antigenic drift and can have low efficacy, particularly in vulnerable populations. Here, we demonstrate that a single administration of a recombinant adenovirus-associated virus (rAAV) vector expressing a computationally optimized broadly reactive antigen (COBRA)-derived influenza H1 hemagglutinin (HA) induces strongly neutralizing and broadly protective antibodies in naïve mice and ferrets with pre-existing influenza immunity. Following a lethal viral challenge, the rAAV-COBRA vaccine allowed for significantly reduced viral loads in the upper and lower respiratory tracts and complete protection from morbidity and mortality that lasted for at least 5 months post-vaccination. We observed no signs of antibody waning during this study. CpG motif enrichment of the antigen can act as an internal adjuvant to further enhance the immune responses to allow for lower vaccine dosages with the induction of unique interferon-producing CD4+ and CD8+ T cells specific to HA head and stem peptide sequences. Our studies highlight the utility of rAAV as an effective platform to improve seasonal influenza vaccines.
Importance: Developing an improved seasonal influenza vaccine remains an ambitious goal of researchers and clinicians alike. With influenza routinely causing severe epidemics with the potential to rise to pandemic levels, it is critical to create an effective, broadly protective, and durable vaccine to improve public health worldwide. As a potential solution, we created a rAAV viral vector expressing a COBRA-optimized influenza hemagglutinin antigen with modestly enriched CpG motifs to evoke a robust and long-lasting immune response after a single intramuscular dose without needing boosts or adjuvants. Importantly, the rAAV vaccine boosted antibody breadth to future strains in ferrets with pre-existing influenza immunity. Together, our data support further investigation into the utility of viral vectors as a potential avenue to improve our seasonal influenza vaccines.
Keywords: adeno-associated virus; influenza vaccines.